Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma

被引：2
|
作者：
Hawkes, Eliza A. [1 ]
Fletcher, Rachel [2 ]
Wood, Andrew [2 ]
Meyer, Stefanie [3 ]
Rule, Simon [4 ]
Zhang, Jingyang [5 ]
Wang, Michael L. [6 ]
机构：
[1] Austin Hlth, Olivia Newton John Canc Res & Wellness Ctr, Heidelberg, Vic, Australia
[2] AstraZeneca, Cambridge, England
[3] AstraZeneca, Waltham, MA USA
[4] AstraZeneca, Mississauga, ON, Canada
[5] AstraZeneca, San Francisco, CA USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Results of a nonrandomized, open-label, phase II study of combined gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Garbo, Lawrence E.
    Flynn, Patrick J.
    MacRae, Margaret A.
    Rauch, Mary A.
    Wang, Yunfei
    Kolibaba, Kathryn S.
    BLOOD, 2007, 110 (11) : 183B - 183B
  • [22] A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma
    Carlo-Stella, Carmelo
    Zinzani, Pier Luigi Luigi
    Sureda, Anna
    Araujo, Luis Francisco
    Casasnovas, Olivier
    Carpio, Cecilia
    Yeh, Su-Peng
    Bouabdallah, Krimo
    Cartron, Guillaume
    Kim, Won Seog
    Cordoba, Raul
    Koh, Youngil
    Re, Alessandro
    Alves, Daniela
    Chamuleau, Martine E. D.
    Le Gouill, Steven
    Lopez-Guillermo, Armando
    Moreira, Maria Ilidia
    Van Der Poel, Marjolein W. M.
    Abbadessa, Giovanni
    Meng, Robin
    Ji, Ran
    Lepine, Lucie
    Saleem, Rao
    Ribrag, Vincent
    BLOOD, 2021, 138
  • [23] A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
    Carlo-Stella, Carmelo
    Zinzani, Pier Luigi
    Sureda, Anna
    Araujo, Luis
    Casasnovas, Olivier
    Carpio, Cecilia
    Yeh, Su-Peng
    Bouabdallah, Krimo
    Cartron, Guillaume
    Kim, Won Seog
    Cordoba, Raul
    Koh, Youngil
    Re, Alessandro
    Alves, Daniela
    Chamuleau, Martine
    Le Gouill, Steven
    Lopez-Guillermo, Armando
    Moreira, Ilidia
    van der Poel, Marjolein W. M.
    Abbadessa, Giovanni
    Meng, Robin
    Ji, Ran
    Lepine, Lucie
    Saleem, Rao
    Ribrag, Vincent
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (01) : 108 - 119
  • [24] Open-label, multicenter Phase II Study to Investigate the Efficacy and Safety of Domatinostat in Combination with Avelumab in Patients with treatment-naive, metastatic Merkel Cell Carcinoma - the MERKLIN 1 Study
    Terheyden, P.
    van Akkooi, A.
    Ascierto, P. A.
    Nghiem, P.
    Henneberg, J.
    Hermann, F.
    Becker, J. C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 45 - 46
  • [25] High Complete Response Rates With Pembrolizumab in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma: Results of an Open-Label, Phase 2 Study
    Martin, Peter
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 6 - 7
  • [26] A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naive Myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay R.
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    BLOOD, 2022, 140 : 3986 - 3987
  • [27] A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    CANCER RESEARCH, 2023, 83 (08)
  • [28] Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study
    Fowler, Nathan
    Nastoupil, Loretta
    de Vos, Sven
    Knapp, Mark
    Flinn, Ian W.
    Chen, Robert
    Advani, Ranjana H.
    Bhatia, Sumeet
    Martin, Peter
    Mena, Raul
    Suzuki, Samuel
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Palomba, M. Lia
    BLOOD, 2015, 126 (23)
  • [29] Sorafenib dose escalation in treatment-naive patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study
    Gore, Martin E.
    Jones, Robert J.
    Ravaud, Alain
    Kuczyk, Markus
    Demkow, Tomasz
    Bearz, Alessandra
    Shapiro, Joann
    Strauss, Uwe Phillip
    Porta, Camillo
    BJU INTERNATIONAL, 2017, 119 (06) : 846 - 853
  • [30] Anlotinib plus carboplatin/pemetrexed in treatment-naive advanced non-squamous NSCLC: An open-label, randomized, phase II study
    Guo, R.
    Gao, W.
    Li, J.
    Liu, Y.
    Liu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S801 - S801
12345